ESR1 and breast carcinoma: In the treatment of ER+ breast cancer, emerging endocrine therapies are being developed to overcome common mechanisms of endocrine resistance, for example, ESR1 mutations, including combination therapies and next-generation selective estrogen receptor degraders (SERDs) and selective estrogen receptor modulators (SERMs), but also other new classes of endocrine therapies [55].